Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Contraception ; 83(1): 55-61, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21134504

ABSTRACT

BACKGROUND: This study was conducted to evaluate the steady-state blood concentrations and potential accumulation of levonorgestrel (LNG) and ethinyl estradiol (EE) administered for up to 84 days and EE alone for 7 additional days as an extended-regimen 91-day oral contraceptive (OC). STUDY DESIGN: An open-label, single-site study was conducted in 30 healthy female volunteers. Subjects received daily doses of 0.15 mg LNG/0.03 mg EE for 84 consecutive days followed by 0.03 mg EE alone for 7 days. Pharmacokinetic (PK) monitoring was conducted on Days 1, 21, 84 and 91. RESULTS: The observed plasma concentrations of LNG after 84 days and of EE after 84 and 91 days were comparable to the steady-state concentrations observed at 21 days. Pharmacokinetic parameters over the 24-h dosing period were similar at all time points measured after achieving steady-state plasma concentrations. CONCLUSION: This study demonstrated that an extended-regimen OC providing 84 days of LNG/EE and 7 days of EE alone has a PK profile similar to a 28-day conventional OC regimen and does not result in any additional accumulation of these hormones.


Subject(s)
Contraceptives, Oral, Combined/pharmacokinetics , Ethinyl Estradiol/pharmacokinetics , Levonorgestrel/pharmacokinetics , Adult , Area Under Curve , Contraceptives, Oral, Combined/administration & dosage , Contraceptives, Oral, Combined/blood , Ethinyl Estradiol/administration & dosage , Ethinyl Estradiol/blood , Female , Half-Life , Humans , Levonorgestrel/administration & dosage , Levonorgestrel/blood , Longitudinal Studies , Middle Aged , Young Adult
2.
Menopause ; 18(4): 393-9, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21107298

ABSTRACT

OBJECTIVE: A randomized, parallel-design study was conducted to determine the pharmacokinetic profile of synthetic conjugated estrogens A (SCE-A) vaginal cream (0.625 mg SCE-A/g) when administered at intervals (1 g once daily for 7 d, then twice weekly) over a 27-day period as compared with the pharmacokinetic profile of 0.3 mg SCE-A tablets administered once daily orally for 27 days. METHODS: Blood samples were collected 48 hours before initial dosing for baseline levels and at multiple occasions during the study until 48 hours after final study dosing (day 29). Maximum plasma concentration, time to maximum plasma concentration (Tmax), and area under the curve from 0 to 24 hours were calculated at days 1, 7, and 27; in addition, area under the curve from 0 to 48 hours was calculated at days 7 and 27, and area under the curve weekly (AUCweekly) values were calculated for both groups. For purposes of comparison, ratios of AUCweekly values for vaginal cream and oral tablets were analyzed. RESULTS: Compared with an oral daily dose of 0.3 mg SCE-A, the steady-state systemic exposure from vaginal cream application was considerably less, with the cream-to-oral ratio being 0.45 for baseline-adjusted (BA) unconjugated estradiol, 0.30 for BA unconjugated estrone, and 0.04 for unconjugated equilin (AUCweekly). At steady-state, the systemic blood levels of BA unconjugated estrone, BA unconjugated estradiol and unconjugated equilin were significantly lower in women who received biweekly application of 1 gm vaginal cream compared to women who took an oral daily dose of 0.3 mg SCE-A tablet. CONCLUSIONS: After intravaginal application of SCE-A vaginal cream, absorption of estrogens was lower compared with absorption after oral administration. At steady state, the systemic exposure of equilin, estradiol, and estrone was significantly lower after twice-weekly administration of 1 g SCE-A vaginal cream compared with that achieved with an oral daily dose of a 0.3 mg SCE-A tablet.


Subject(s)
Estradiol Congeners/pharmacokinetics , Postmenopause , Tablets/administration & dosage , Vaginal Creams, Foams, and Jellies/administration & dosage , Adult , Aged , Chromatography, High Pressure Liquid , Equilin/blood , Estradiol/blood , Estradiol Congeners/administration & dosage , Estrogens/administration & dosage , Estrogens/pharmacokinetics , Estrone/blood , Female , Humans , Mass Spectrometry , Middle Aged
3.
Contraception ; 77(1): 34-9, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18082664

ABSTRACT

BACKGROUND: The study was conducted to evaluate the effects of low-dose estrogen compared to placebo on ovarian activity during the traditional 7-day hormone-free interval (HFI) of an oral contraceptive (OC). STUDY DESIGN: Women were randomized to placebo or low-dose estrogen for 7 days during the HFI. Serum levels of estradiol, follicle-stimulating hormone (FSH), luteinizing hormone and inhibin B were obtained before, during and after treatment. RESULTS: Mean hormone levels remained constant or only increased slightly for the low-dose estrogen group compared to greater more sustained increases observed for the placebo group. Estradiol, FSH and inhibin B levels were substantially higher for those on placebo. Differences were most noticeable by the end of the HFI and persisted into the subsequent cycle. CONCLUSION: Subjects receiving low-dose estrogen for 7 days during the HFI demonstrated more pronounced ovarian suppression compared to placebo as evidenced by attenuation of increases in serum inhibin B, FSH and estradiol levels.


Subject(s)
Contraceptives, Oral, Hormonal/administration & dosage , Contraceptives, Oral, Sequential/pharmacology , Ovary/drug effects , Adolescent , Adult , Estradiol/blood , Female , Follicle Stimulating Hormone/blood , Humans , Inhibins/blood , Inhibins/drug effects , Placebos/administration & dosage , Prospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...